INCELL Pioneering the World’s First Effective Cell Therapy for ALS
San Antonio, Texas, July 25, 2024 – ALS, or amyotrophic lateral sclerosis, is defined by the ALS Association (als.org) as a progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord. ALS symptoms vary and patients may lose the ability to speak, eat, move and breathe. There is no cure. The Mayo Clinic reports (mayoclinic.org) that no treatments can reverse ALS damage, but they may slow the progression of disease symptoms or help prevent complications. INCELL is committed to tackling innovative ALS therapy. [Read more…]
CytoMed Therapeutics Acquires Cord Blood Banking Licence and Assets to Entrench Its Strategy in Allogeneic, Off-the-shelf Donor-derived Gamma Delta (γδ) T Cells Technology for Solid and Liquid Cancers
Another Patent Granted for CytoMed’s Allogeneic Induced Pluripotent Stem Cell (“iPSC”)-derived Hybrid Gamma Delta Natural Killer T (γδ NKT) cells technology
SINGAPORE, July 17, 2024 — CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor blood-derived, cell-based allogeneic therapies for the treatment of various cancers and aging-related diseases, has, through its wholly owned subsidiary, IPSC Depository Sdn Bhd acquired the licence and certain assets of Cellsafe International Sdn Bhd (In Liquidation) (“CISB”), a Malaysian cord blood bank for a cash consideration of approximately RM 2.3 million or US$ 490,000 to be funded from internal cash resources. [Read more…]
iRegene Receives IND approval from U.S. FDA to Start Clinical Trial for Parkinson’s Disease
WUHAN, China, June 24, 2024 — On June 20 (UTC-4), the U.S. Food and Drug Administration (FDA) approved the IND application for NouvNeu001, a cell therapy product from iRegene therapeutics targeting Parkinson’s Disease. This marks a significant milestone as NouvNeu001 becomes the world’s first chemically induced allogeneic cell therapy product to enter clinical stages for Parkinson’s disease in the US. Previously, the “Combined Phase I/II Clinical Study” of NouvNeu001 had already received approval from China NMPA in August 2023 and demonstrated positive safety and efficacy data in its Phase I trials. On June 20, 2024, iRegene further announced IND approval of NouvNeu001 by the U.S. FDA for the treatment of mid-to-late stage of Parkinson’s disease. [Read more…]
Creative Medical Technology Announces iPSCelz® Program Has Generated iPSC Derived Islet Cells that Produce Human Insulin
PHOENIX, June 24, 2024 — Creative Medical Technology Holdings, Inc. (“Creative Medical Technology” or the “Company”) (NASDAQ: CELZ), a leading commercial stage biotechnology company focused on a regenerative approach to immunotherapy, urology, neurology, and orthopedics, today announced that it has successfully generated human induced pluripotent stem cells (iPSC)-derived Islet Cells that produce human insulin. [Read more…]
- « Previous Page
- 1
- …
- 100
- 101
- 102
- 103
- 104
- …
- 340
- Next Page »